Antares Pharma to Report First Quarter 2021 Financial and Operating Results
April 27, 2021 08:30 ET
|
Antares Pharma, Inc.
EWING, N.J., April 27, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced it will release its first quarter 2021...
Antares Pharma Appoints Dr. Peter Richardson as Executive Vice President, Research and Development and Chief Medical Officer
April 26, 2021 08:30 ET
|
Antares Pharma, Inc.
EWING, N.J., April 26, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced the appointment of Peter Richardson, MRCP, as...
Antares Pharma Reports Fourth Quarter and Full-Year 2020 Financial and Operating Results
March 02, 2021 07:00 ET
|
Antares Pharma, Inc.
Full-Year 2020 Revenue Increases 21% Year-Over-Year to $149.6 Million Full-Year 2020 Net Income Before Income Taxes of $9.9 Million, or $0.06 per Share Full-Year 2020 Net Income of $56.2 Million,...
Antares Pharma to Present at Two Upcoming Investor Conferences
February 24, 2021 16:30 ET
|
Antares Pharma, Inc.
EWING, N.J., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief...
Antares Pharma to Report Fourth Quarter and Full-Year 2020 Financial and Operating Results
February 23, 2021 08:30 ET
|
Antares Pharma, Inc.
EWING, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced it will release its fourth quarter and...
Antares Pharma to Participate in the SVB Leerink 10th Annual Virtual Global Healthcare Conference
February 17, 2021 08:30 ET
|
Antares Pharma, Inc.
EWING, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief...
Antares Pharma Announces Full-Year 2021 Revenue Guidance of $175-200 Million
January 11, 2021 08:00 ET
|
Antares Pharma, Inc.
EWING, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced guidance for full-year 2021 and expects...
Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 23, 2020 16:05 ET
|
Antares Pharma, Inc.
EWING, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief...
Antares Pharma to Present at the Jefferies Virtual London Healthcare Conference
November 10, 2020 16:30 ET
|
Antares Pharma, Inc.
EWING, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief...
Antares Pharma Reports Strong Third Quarter 2020 Financial and Operating Results
November 05, 2020 07:00 ET
|
Antares Pharma, Inc.
Third Quarter 2020 Revenue Increases 17% Year-Over-Year to $40.0 Million Third Quarter 2020 Net Income of $5.0 Million, or EPS of $0.03 EWING, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) --...